Pesquisar
Tenax Therapeutics Inc
TENXAdicionar à lista de desejos
15.460USD
+2.170+16.33%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
375.30MValor de mercado
PerdaP/L TTM
Mais detalhes de Tenax Therapeutics Inc Empresa
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Informações de Tenax Therapeutics Inc
Código da empresaTENX
Nome da EmpresaTenax Therapeutics Inc
Data de listagemOct 28, 1993
CEOGiordano (Christopher T)
Número de funcionários4
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 28
Endereço101 Glen Lennox Drive
CidadeCHAPEL HILL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27517
Telefone19198552100
Sitehttp://www.tenaxthera.com/
Código da empresaTENX
Data de listagemOct 28, 1993
CEOGiordano (Christopher T)
Executivos da empresa Tenax Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Tenax Therapeutics Inc?
Os cinco principais acionistas de Tenax Therapeutics Inc são: Dr. Stuart Rich, M.D.
Quantas instituições possuem ações da Tenax Therapeutics Inc (TENX)?
Em 2026Q1, 74 instituições possuíam ações da Tenax Therapeutics Inc, com valor de mercado aproximado de 11.71M, representando 51.15% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 5305648.00.